ArticleJournal of pharmacokinetics and pharmacodynamics2009
Simultaneous optimal experimental design on dose and sample times.
Article in Journal of pharmacokinetics and pharmacodynamics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.Clinical pharmacokinetics · 2015Pooled it
- Model-based evaluation of drug-induced QTc prolongation for compounds in early development.British journal of clinical pharmacology · 2015Trial
- Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.British journal of clinical pharmacology · 2013Trial
- Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models.The AAPS journal · 2019Article
- Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.Clinical pharmacokinetics · 2019Review
- Reduced and optimized trial designs for drugs described by a target mediated drug disposition model.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- Analysis of opioid consumption in clinical trials: a simulation based analysis of power of four approaches.Journal of pharmacokinetics and pharmacodynamics · 2017Article
- Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.British journal of clinical pharmacology · 2014Article
- Optimizing disease progression study designs for drug effect discrimination.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- Simultaneous optimal experimental design for in vitro binding parameter estimation.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.Journal of pharmacokinetics and pharmacodynamics · 2012Article
- Optimised protocol design for the screening of analgesic compounds in neuropathic pain.Journal of pharmacokinetics and pharmacodynamics · 2012Article
- Optimal design in population kinetic experiments by set-valued methods.The AAPS journal · 2011Article
- D-optimal designs for parameter estimation for indirect pharmacodynamic response models.Journal of pharmacokinetics and pharmacodynamics · 2009Article
- Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design.Journal of pharmacokinetics and pharmacodynamics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal experimental design can be used for optimizing new pharmacokinetic (PK)-pharmacodynamic (PD) studies to increase the parameter precision. Several methods for optimizing non-linear mixed effect models has been proposed previously but the impact of optimizing other continuous design parameters, e.g. the dose, has not been investigated to a large extent. Moreover, the optimization method (sequential or simultaneous) for optimizing several continuous design parameters can have an impact on the optimal design. In the sequential approach the time and dose where optimized in sequence and in the simultaneous approach the dose and time points where optimized at the same time. To investigate the sequential approach and the simultaneous approach; three different PK-PD models where considered. In most of the cases the optimization method did change the optimal design and furthermore the precision was improved with the simultaneous approach.
Indexed as
Identifiers
19319484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.